Follow us on Twitter
twitter icon@FreshPatents


Receptor patents

      

This page is updated frequently with new Receptor-related patent applications.




 Movable type method applied to protein-ligand binding patent thumbnailnew patent Movable type method applied to protein-ligand binding
Disclosed herein is a method of estimating the pose of a ligand in a receptor comprising identifying all possible atom pairs of protein-ligand complexes in a given configuration space for a system that comprises proteins; creating a first database and a second database; where the first database comprises associated pairwise distant dependent energies and where the second database comprises all probabilities that include how the atom pairs can combine; combining the first database with the second database via statistical mechanics to accurately estimate binding free energies as well as a pose of a ligand in a receptor; and selecting a protein-ligand complex for further study.. .
Board Of Trustees Of Michigan State University


 Image forming apparatus and image forming method patent thumbnailnew patent Image forming apparatus and image forming method
An image forming apparatus includes an electrophotographic photoreceptor, a charging unit; an electrostatic latent image forming unit, a developing unit that stores a developer containing a toner, a transfer unit, a cleaning unit and a fixation unit, wherein the toner has a sea and island structure of a sea portion containing the binder resin and an island portion containing the release agent, a maximum frequent value of the eccentricity b of the island portion containing the release agent is in a range of from 0.75 to 0.95, and a skewness of the eccentricity b is in a range of from −1.10 to −0.50.. .
Fuji Xerox Co., Ltd.


 Insulin receptor substrate 1 (irs1) protein srm/mrm assay patent thumbnailnew patent Insulin receptor substrate 1 (irs1) protein srm/mrm assay
The current disclosure provides for specific peptides from the insulin receptor substrate 1 (irs1) protein and the derived ionization characteristics of those peptides that are particularly advantageous for quantifying the irs1 directly in formalin fixed biological samples by the method of selected reaction monitoring (srm) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells.
Expression Pathology, Inc.


 G-protein coupled receptor-associated diagnostics and therapeutics for b-cell chronic lymphocytic leukemia patent thumbnailnew patent G-protein coupled receptor-associated diagnostics and therapeutics for b-cell chronic lymphocytic leukemia
The disclosure provides diagnostic and therapeutic agents for chronic lymphocytic leukemia (cll). Further provided are biomarkers and a biomarker panel comprising g-protein coupled receptors (gpcrs) specifically expressed by cll cells.
The Regents Of The University Of California


 Lightning receptor for a wind turbine blade patent thumbnailnew patent Lightning receptor for a wind turbine blade
The invention provides a lightning receptor arrangement (11, 12) for a wind turbine blade (10) comprising at least a self-threading screw (21) having a head (23) and a threaded shaft (25) as a the external metallic receptor element for receiving a lightning strike in one side of the wind turbine blade (10) and an internal element comprising an electrically conductive block (20) configured with at least an unthreaded hole (41) for cooperating with said threaded shaft (25) and connected to a down conductor (18) of a grounding arrangement. The internal element is joined to at least a shell (17) of the wind turbine blade (10) with an adhesive force capable of withstanding the torque applied to the self-threading screw (21) for threading it to the unthreaded hole (41)..
Gamesa Innovation & Technology, S.l.


 Aflatoxin templates, molecularly imprinted polymers, and methods of making and using the same patent thumbnailnew patent Aflatoxin templates, molecularly imprinted polymers, and methods of making and using the same
Molecularly imprinted polymers (mips) are materials exhibiting molecular recognition of a target molecule. Mips are synthesized in the presence of an aflatoxin template, a mimic to the targeted molecule, used as an imprint that is further washed away with suitable solvent after completion of the polymerization process, leaving a cavity in the polymer of the same stereochemistry, functionality and morphology to the template.
Alltech, Inc.


 Anti-toso chimeric antigen receptor and its use patent thumbnailnew patent Anti-toso chimeric antigen receptor and its use
In a first aspect, the present invention relates to genetically modified t-cells having a chimeric antigen receptor (car) in a method for adoptive cell therapy for treating toso+ cancer, like b-cell leukemia/lymphoma, in a subject in need thereof. In particular, the present invention relates to a genetically engineered t-cell containing and expressing a specific chimeric antigen receptor being toxic to toso+ cancer cells while being less toxic or non-toxic to toso+ non-cancer cells, in particular, being non-toxic to normal b cells and its precursors.
Universitaet Zu Koeln


 Compositions and methods of use for therapeutic antibodies patent thumbnailnew patent Compositions and methods of use for therapeutic antibodies
The present invention relates to antibodies that specifically bind to the baff receptor (baffr). The invention more specifically relates to specific antibodies that are baffr antagonists with in vivo b cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting b cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas..
Novartis Ag


 Anti-ox40 antibodies and methods of use thereof patent thumbnailnew patent Anti-ox40 antibodies and methods of use thereof
The present disclosure provides antibodies that specifically bind to human ox40 receptor (ox40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human ox40 and modulate ox40 activity, e.g., enhance, activate, or induce ox40 activity, or reduce, deactivate, or inhibit ox40 activity.
Memorial Sloan-kettering Cancer Center


 Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof patent thumbnailnew patent Protein binding domains stabilizing functional conformational states of gpcrs and uses thereof
The present invention relates to the field of gpcr structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a g-protein-coupled receptor (gpcr).
The Board Of Trustees Of The Leland Stanford Junior University


new patent

New monoclonal antibodies against the receptor dec-205 of chicken dentritic cells

The invention relates to the production and the characterisation of new murine monoclonal antibodies that recognize the domain ctd-2 (seq id no: 1) of the cell receptor dec-205 of dendritic cells in chickens (gallus gallus), pigs, (sus scrofa) and humans (homo sapiens). The invention also relates to the capacity of the new antibodies to direct and modulate the immune response at different levels in chickens (gallus gallus) and pigs (sus scrofa), as well as recognising the receptor dec-205 in dentritic cells and cell lines in humans, in addition, the invention is used to quickly produce a specific humoral immune response against hemaglutinina h5 of the h5n2-type avian flu virus..
Universidad Nacional AutÓnoma De MÉxico

new patent

Antibodies comprising chimeric constant domains

Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
Regeneron Pharmaceuticals, Inc.

new patent

Compositions and methods for immunomodulation in an organism

The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut

new patent

Glucagon analogues

The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes.
Boehringer Ingelheim International Gmbh

new patent

Compositions and methods for treating acute and chronic pain by local antagonism of cgrp receptors, or combination with sodium channel inhibition or with anti-inflammatory agents

The present invention provides compositions, and methods for local administration of certain peptides or combination with certain small molecules that produce analgesia and anti-inflammation in a mammal. Exemplary polypeptides provide peripheral analgesia and anti-inflammation when administered via local topical, subcutaneous, intradermal, or intranasal administration, to provide analgesia and anti-inflammation.
Afasci, Inc.

new patent

Homogeneous preparations of il-31

Homogeneous preparations of human and murine il-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity..
Zymogenetics, Inc.

new patent

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

new patent

Interaction of draxin and y-netrins

This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the interaction between draxin, particularly fragments binding to γ-netrins comprising seq id no.: 1, 2 or 3, and variants thereof, with γ-netrins, and the use of this interaction to disrupt γ-netrin/netrin receptor interactions.
Max-planck-gesellschaft Zur Foerderung Der Wissens Chaften E.v.

new patent

Immune adjustment compound, use thereof and pharmaceutical composition comprising same

The present invention provides a compound represented by formula i, wherein r is a halogen element or a c1-c6 alkyl group. The compound has s1p1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation s1p1 receptor agonist.
Suzhou Connect Biopharmaceuticals, Ltd.

new patent

Heterocyclic estrogen receptor modulators and uses thereof

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors..
Genentech, Inc.

new patent

Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising same and use thereof

The present invention relates to a pyrrole-substituted indolone derivative, a preparation method therefor, a composition comprising the derivative, and use thereof. The pyrrole-substituted indolone derivative has a structure shown in formula (i) below.
Shijiazhuang Yiling Pharmaceutical Co., Ltd.

new patent

Toll-like receptor 8 agonists

Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr8 agonists.

new patent

Transportation apparatus, printing apparatus, and transportation amount acquisition method

A transportation apparatus comprises: a transportation section that transports continuous paper in a transportation direction intersecting with a shaft direction of a transportation roller by operating the transportation roller; an imaging section that includes plural photoreceptor elements and captures an image of the continuous paper transported by the transportation section, the photoreceptor elements being arranged in a first direction and a second direction, the first direction intersecting with the shaft direction, the second direction intersecting with the first direction; and a transportation amount acquisition section that acquires a transportation amount of the continuous paper in the transportation direction on the basis of the image captured by the imaging section, wherein the transportation amount acquisition section acquires the transportation amount of the continuous paper by correcting a movement amount of the continuous paper in the first direction with a correction value that changes in accordance with orientation of the first direction.. .
Seiko Epson Corporation

new patent

Image generating and playing-piece-interacting assembly

A baseplate assembly, used with releasably coupleable playing pieces, includes a baseplate operably coupled to an image generating device. The baseplate includes a display region, having playing pieces coupling elements, and means for transmitting images generated by the image generating device to the display region.
Technologyone, Inc.

new patent

Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation

A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of

new patent

Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases

A fusion protein comprising an antigen-presenting cell (apc)-binding domain or a cd91 receptor-binding domain, a translocation peptide, a fusion antigen, an endoplasmic reticulum retention sequence, and optionally a nuclear export signal is disclosed. The fusion antigen comprises a porcine reproductive and respiratory syndrome virus (prrsv) orf7 antigen, a prrsv orf1b antigen, a prrsv orf6 antigen, and a prrsv orf5 antigen.
Reber Genetics Co., Ltd.

new patent

Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

new patent

Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to fusion proteins comprising an epidermal growth factor receptor variant iii (egfrviii) polypeptide and a mesothelin polypeptide, and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins.
Aduro Biotech, Inc.

new patent

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies.
Oncomed Pharmaceuticals, Inc.

new patent

Cytokine receptor peptides, compositions thereof and methods thereof

The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.

new patent

Targeted oesophageal administration of zn-alpha2-glycoproteins (zag), methods and formulations thereof

The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as hypoglycemia, obesity, diabetes, and the like by targeted administration to the oesphagus of a subject of zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.. .
Aston University

new patent

Compositions for treatment of atrophic vaginitis, peri- and post-menopausal dyspareunia, and/or oophorectomized females and treatment methods therewith

Compositions for topical administration to a urogenital area and/or in a vagina are disclosed. The compositions includes a therapeutically effective amount of a selective estrogen receptor modulator (serm), an intracellular carrier for carrying the serm into a cell, and a therapeutically effective amount of a cellular anti-inflammatory agent.
Durga Enterprises, Llc

new patent

Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung

The present disclosure relates to methods for treating cancer by intrapulmonary administration of a polynucleotide toll-like receptor 9 agonist. The methods of the present disclosure are suitable for treating primary cancer of the lung, as well as metastatic cancer to the lung and extra pulmonary cancers thereof.
Dynavax Technologies Corporation

new patent

Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and monitoring sensitivity of anticancer drug

The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (rip3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a rip3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells.
Dong Wha Pharm. Co., Ltd.

new patent

Selective estrogen receptor modulators with short half-lives and uses thereof

The present invention relates to the long-term administration of a selective estrogen receptor modulator (serm) with a short half-life for the treatment of a variety of estrogen receptor-mediated conditions. The serm may be administered at a concentration at or below that of a serm with a long half-life in order to achieve an equivalent therapeutic effect..
Repros Therapeutics Inc.

new patent

Novel use of sigma-1 receptor agonist compounds

The present invention is directed to compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. In particular, embodiments of the present invention relate to the use of sigma-1 receptor agonists for use in the treatment or prevention of progressive fibrosis characterized by the overproliferation of ecm producing cells, e.g.
Semmelweis Egyetem

new patent

Treatment of breast cancer with liposomal irinotecan

Provided are methods for treating breast cancer in a patient by administering effective amounts of liposomal irinotecan sucrosofate (mm-398). The breast cancer may be triple negative breast cancer (tnbc), estrogen receptor/progesterone receptor (er/pr) positive breast cancer, er-positive breast cancer, or pr-positive breast cancer, or metastatic breast cancer..
Merrimack Pharmaceuticals, Inc.

new patent

Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Compounds of formula i, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.

new patent

Aminoester derivatives

Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratrory tract.. .
Chiesi Farmaceutici S.p.a.

new patent

Compositions and methods for the treatment of addiction and other neuropsychiatric disorders

The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced during menopause or associated with the menstrual cycle. Regardless of the precise formulation, the compositions of the invention can include at least one active ingredient that targets the hypothalamo-pituitary-adrenal (hpa) axis and at least one active ingredient that targets the prefrontal cortex.
Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College

new patent

Aminoester derivatives

Compounds of formula (i) defined herein are both phosphodiesterase 4 (pde4) enzyme inhibitors and muscarinic m3 receptor antagonists and are useful for treating diseases of the respiratory tract.. .
Chiesi Farmaceutici S.p.a.

new patent

Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases

A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression.
Qaam Pharmaceuticals, Llc

new patent

Treatment of respiratory disorders using ror-gamma inhibitors

The present patent application relates to treatment of a respiratory disorder using retinoid-related orphan receptor gamma t (ror-gamma) modulators. Particularly, the present patent application relates to treatment of a respiratory disorder using a rorγ inhibitor, wherein the rorγ inhibitor is administered by an inhalation route to a subject in need thereof..
Glenmark Pharmaceuticals S.a.

new patent

Compositions and methods for reducing visual loss

The described invention provides a method for reducing visual loss and for treating one or more of adverse consequence of an eye disease, including abnormal intraocular pressure, retinal vascular disease, retinal ganglion cell death, or a combination thereof in order to reduce visual loss. The method entails providing a flowable particulate composition that contains a particulate formulation comprising a plurality of particles of uniform size distribution, a therapeutic amount of a therapeutic agent selected from a voltage-gated calcium channel antagonist, an endothelin receptor antagonist, or a combination thereof, and optionally an additional therapeutic agent, wherein the particles are of uniform size distribution, and wherein each particle comprises a matrix; and a pharmaceutically acceptable carrier.
Edge Therapeutics, Inc.

new patent

Solid pharmaceutical compositions of androgen receptor antagonists

The present invention belongs to the field of pharmaceutical industry and relates to a solid pharmaceutical composition comprising androgen receptor antagonists, e.g. Enzalutamide or arn-509, as well as to processes for preparing the same.
Lek Pharmaceuticals D.d.

new patent

Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph

This invention provides methods of treating androgenetic alopecia (aga), acne, rosacea, prostate cancer, and benign prostatic hypertrophy (bph), comprising the step of contacting a subject with a compound or composition capable of decreasing prostaglandin d2 (pgd2) level or activity, a downstream signaling or receptor pathway thereof, or prostaglandin d2 synthase level or activity; methods of stimulating hair growth, comprising the step of contacting a subject with a compound or composition capable of increasing or decreasing the activity or level of a target gene of the present invention, or with a protein product of the target gene or an analogue or mimetic thereof; and methods of testing for aga and evaluating therapeutic methods thereof, comprising measuring pgd2 levels.. .
The Trustees Of The University Of Pennsylvania

new patent

Compositions for reducing hair loss and/or increasing hair regrowth

The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% of a 5α-reductase inhibitor or an androgen receptor antagonist, and 0.01% to 15% of a prostaglandin analogue. In one embodiment, the prostaglandin analogue is latanoprost.
Triple Hair, Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9616

file did exist - file did put2867

3 - 1 - 60